Shilpa Medicare Limited Earnings Summary — Q4 FY2026
Shilpa Medicare Achieves Record Quarterly Profit and Significant Revenue Expansion in Q4
Quarterly Business Intelligence
AI Quarterly Scorecard™
Computed deterministically from the last 10 reported quarters.
Quarterly Business Momentum
- Revenue has increased for 5 consecutive quarters.
- Revenue of ₹466 Cr is 44.9% higher year-on-year.
- Revenue has compounded at 23.1% annualised over the last 10 quarters.
- Revenue is at its highest level in 10 quarters.
- Net profit of ₹101 Cr is 115.1% above the same quarter last year.
- Profit growth is outpacing revenue growth, pointing to positive operating leverage.
- Net profit has compounded at 87.6% annualised across the period.
- Operating margin stands at 29.3% in Q1 FY2027.
- Operating margin expanded by 98 bps year-on-year.
- Over the last two years operating margin has expanded by 533 bps.
- PBT margin is 21.1%.
- Expense growth of 42.9% remained below revenue growth of 44.9%.
- Operating profit of ₹136 Cr is 49.9% higher year-on-year.
- Operating leverage continues to improve.
- 6 of the last 6 measured quarters delivered year-on-year revenue growth.
- Overall quarterly business momentum scores 79/100 (Strong) on the latest 10 quarters.
- Business momentum remains positive heading into the next quarter.
Quarterly Financials
Last 10 Reported Quarters • All figures in ₹ Crore • Margins in %
| Metric | Trend | Latest Q1 FY2027 | Q4 FY2026 | Q3 FY2026 | Q2 FY2026 | Q1 FY2026 | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 | Q4 FY2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | Improving | 466 | 437 | 410 | 370 | 321 | 331 | 319 | 344 | 293 | 292 |
| Expenses | Improving | 330 | 317 | 296 | 262 | 231 | 252 | 239 | 258 | 223 | 222 |
| Operating Profit | Improving | 136 | 120 | 114 | 108 | 91 | 79 | 81 | 86 | 70 | 70 |
| Operating Margin | Stable | 29.3% | 27.4% | 27.9% | 29.2% | 28.3% | 23.9% | 25.3% | 24.9% | 23.9% | 24.0% |
| Other Income | Volatile | 9 | 45 | -13 | 2 | 6 | -21 | 2 | 5 | 10 | 9 |
| Interest | Softening | 12 | 14 | 11 | 16 | 19 | 14 | 12 | 26 | 24 | 24 |
| Depreciation | Improving | 35 | 31 | 30 | 30 | 29 | 29 | 29 | 28 | 27 | 27 |
| Profit Before Tax | Volatile | 98 | 120 | 61 | 64 | 50 | 15 | 42 | 37 | 29 | 28 |
| Tax | Volatile | -3 | 13 | 16 | 20 | 3 | 1 | 10 | 19 | 15 | 3 |
| Net Profit | Volatile | 101 | 108 | 45 | 44 | 47 | 15 | 32 | 18 | 14 | 25 |
| Net Margin | Volatile | 21.7% | 24.7% | 10.9% | 11.9% | 14.6% | 4.4% | 9.9% | 5.2% | 4.8% | 8.4% |
Key Takeaways
- Revenue reached a record high of ₹437 Cr in Q4 FY2026, marking a 32% growth year-on-year.
- Net Profit surged to ₹108 Cr, aided by strong operational performance and significant other income of ₹45 Cr.
- Operating Profitability remains robust at 27%, consistently staying above the 20% threshold seen in previous years.
- Tax expense for the quarter was exceptionally low at 10%, contributing to the bottom-line strength.
- Interest costs remained relatively stable at ₹14 Cr compared to the prior quarter, despite a slight increase in total borrowings.
- The company continues its transition from high capital expenditure to a commercialization phase in biologics and oncology.
- Total Assets grew to ₹3,706 Cr as the company capitalized significant portions of its Capital Work-in-Progress (CWIP).
Management Guidance
Management is focusing on shifting from a capex-heavy cycle to a realization phase, leveraging technical expertise in oncology APIs and regulated markets.
Sentiment Shift
Improving
The sharp recovery in profitability (TTM profit growth >165%) and successful margin floor of 25-28% indicates that previous R&D investments are now commercializing.
Outlook
The outlook remains constructive as the company moves up the value chain into Biologics and Oral Disintegrating Films while maintaining a strong foothold in niche Oncology APIs.
From the Annual Report (Key Quotes)
“Shilpa Medicare is in a critical transition phase from a high-capex cycle to a realization phase.”
“Recent performance shows a sharp recovery, with trailing twelve-month profit growth exceeding 165%.”
“Strategic impact of recent facility approvals suggests management is navigating regulatory hurdles effectively.”
Official Quarterly Documents
This summary is AI-generated from Shilpa Medicare Limited's latest quarterly filing and earnings call. For informational purposes only — not investment advice.